SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

ONVO RSS Feed
Add ONVO Price Alert      Hide Sticky   Hide Intro
Moderator: dshade, Dadx4
Search This Board: 
Last Post: 2/22/2017 1:17:00 PM - Followers: 323 - Board type: Free - Posts Today: 2

WELCOME TO THE ORGANOVO BOARD


 
     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.

COMPANY PROFILE via YouTube
http://www.youtube.com/watch?feature=player_embedded&v=-A-uH15bQZw

 
ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014


IR and Media Contacts:
Investor Relations Contact: [email protected]
Media Contact: [email protected]

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994


For all the latest company information, details, news, please visit http://www.organovo.com

 
Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:

Science

Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.

 

World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  

 

NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

http://www.invetech.com.au/portfolio/life-sciences/3d-bioprinter-world-first-print-human-tissue/
http://techli.com/2012/07/organovo-bioprinting/#.
https://www.youtube.com/watch?v=1O3c3pUg0L8 (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ONVO News: Statement of Changes in Beneficial Ownership (4) 02/21/2017 06:05:27 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 02/21/2017 06:04:05 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 02/21/2017 06:02:43 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 02/21/2017 06:00:27 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 02/21/2017 05:58:41 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 02/21/2017 06:05:27 PM
PostSubject
#9723  Sticky Note Organovo Signs Exclusive Distributor Agreement With Cosmo Bio (Japan) Dadx4 12/14/16 08:25:51 AM
#6071  Sticky Note ONVO Kidney news & Profile videos dshade 05/24/14 12:15:04 PM
#9879   It's always about revenue growth, which is why WHP03 02/22/17 01:17:00 PM
#9878   The interest will be subdued thewind 02/22/17 12:33:34 PM
#9877   Not sure about the latter being accurate, but WHP03 02/21/17 09:04:38 PM
#9875   so they tooted their horn? thewind 02/21/17 10:33:35 AM
#9874   Organovo Publishes Data Describing Physiology of 3D Bioprinted Dadx4 02/21/17 08:56:56 AM
#9873   ONVO's founder is already doing that (to produce WHP03 02/19/17 07:46:54 PM
#9872   I say they team up with the Iowa tyfoidhana 02/18/17 11:54:26 PM
#9871   It occurs to me Organovo could team up RandolRocketman 02/18/17 06:16:33 PM
#9870   Investors hub is dying a slow death. thewind 02/16/17 07:25:56 AM
#9869   I posted it twice because I was trying WHP03 02/15/17 09:57:08 AM
#9868   Since you wrote this twice I can see thewind 02/14/17 09:39:55 PM
#9867   ONVO has raised $74 million of their entitled WHP03 02/14/17 07:41:58 PM
#9866   $ONVO Updated survey results settings so anyone with WHP03 02/14/17 01:44:18 PM
#9865   The survey results are bullish. Yes Moo WHP03 02/14/17 09:39:10 AM
#9864   I won't even take the time to read CIMA7 02/14/17 03:13:37 AM
#9863   ONVO has raised $74 million of their entitled WHP03 02/14/17 12:54:30 AM
#9862   To conclude, the Total Outstanding share count increased Short_S/P_2018 02/13/17 11:04:59 PM
#9861   10Q - Middle of Pg. 12 - Short_S/P_2018 02/13/17 10:53:52 PM
#9860   I saw the share count grow... thewind 02/13/17 08:07:14 PM
#9859   I couldn't agree with you more! The conference Short_S/P_2018 02/13/17 06:34:22 PM
#9858   Did cashmoo do all 20 surveys ? thewind 02/13/17 01:32:15 PM
#9857   Survey Results so far (19 responses): WHP03 02/13/17 12:32:56 PM
#9856   $3.00 is a support level if it holds? rayank 02/13/17 11:36:44 AM
#9855   I feel like cashmoo over there ruins the thewind 02/13/17 06:40:35 AM
#9854   If their feelings are based on the share CIMA7 02/13/17 04:14:43 AM
#9853   ONVO Post Earnings Survey... interested to see how WHP03 02/12/17 11:32:35 PM
#9851   Barring any news release we won't have an pupuguru 02/11/17 12:59:21 PM
#9850   $ONVO New ascending SUP from $1.60 low terminates WHP03 02/11/17 12:01:37 PM
#9849   The same applies though thewind 02/11/17 09:12:13 AM
#9848   I was worried about pharma being at risk RandolRocketman 02/11/17 04:18:06 AM
#9847   It's a gamble. That's for sure. CIMA7 02/10/17 09:33:33 PM
#9846   Or they buy a bio printer thewind 02/10/17 08:34:31 PM
#9845   Why wouldn't big pharma make their life difficult thewind 02/10/17 08:26:10 PM
#9844   "proof of concept" bigideaportugal 02/10/17 06:39:12 PM
#9843   Don't be silly,, this will not go bankrupt. bigideaportugal 02/10/17 06:38:39 PM
#9842   When this technology is called "disruptive" thewind 02/10/17 05:26:54 PM
#9841   I meant .05 Ballgame 02/10/17 03:58:19 PM
#9840   Just got harder to get to $5 by RallyTheMarket 02/10/17 03:57:31 PM
#9839   Can you better define what you means when WHP03 02/10/17 03:42:38 PM
#9838   But you are talking sense thewind 02/10/17 09:52:42 AM
#9837   Unfortunately future revs guidance isn't making investors too Ballgame 02/10/17 09:50:11 AM
#9836   Be greedy when others are fearful. I picked gimmekimmy 02/10/17 09:23:47 AM
#9835   I understand your concerns. I don't believe bettyfordallstar 02/10/17 06:37:08 AM
#9834   Simple questions I didn't hear on the conference call... thewind 02/09/17 07:31:04 PM
#9833   "We also added one global Top 25 pharma rayank 02/09/17 06:56:36 PM
#9832   did i hear that right,, they added 6 bigideaportugal 02/09/17 06:21:16 PM
#9831   Yes with a delay in revenue, we just rayank 02/09/17 06:17:33 PM
#9830   Over reaction to delay in revenue, not bettyfordallstar 02/09/17 06:03:13 PM
#9829   "The results exceeded Wall Street expectations. The average rayank 02/09/17 05:51:40 PM
#9828   20% rayank 02/09/17 05:48:27 PM
PostSubject